Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
Inv. presentation

Galera Therapeutics, Inc. (GRTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates"
08/10/2023 8-K Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Departure of Directors or Ce...
Docs: "Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese"
06/28/2023 SC 13G/A Novo Holdings A/S reports a 4.9% stake in Galera Therapeutics, Inc.
05/11/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates"
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/08/2023 ARS Form ARS - Annual Report to Security Holders:
03/08/2023 10-K Annual Report for the period ended December 31, 2022
03/08/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates"
02/13/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/09/2023 SC 13D Blackstone Holdings I/II GP L.L.C. reports a 7.8% stake in Galera Therapeutics, Inc.
01/25/2023 8-K Other Events  Interactive Data
12/12/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis"
12/09/2022 8-K Quarterly results
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/09/2022 8-K Quarterly results
10/26/2022 8-K Quarterly results
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/16/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/16/2022 8-K Quarterly results
04/28/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/10/2022 10-K Annual Report for the period ended December 31, 2021
03/10/2022 8-K Quarterly results
02/14/2022 SC 13G/A CITADEL ADVISORS LLC reports a 0.6% stake in Galera Therapeutics, Inc.
02/11/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/11/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy